OPILL Drug Patent Profile
✉ Email this page to a colleague
When do Opill patents expire, and when can generic versions of Opill launch?
Opill is a drug marketed by Laboratoire Hra and is included in one NDA.
The generic ingredient in OPILL is norgestrel. There are twenty-five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the norgestrel profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OPILL?
- What are the global sales for OPILL?
- What is Average Wholesale Price for OPILL?
Summary for OPILL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 107 |
| Drug Prices: | Drug price information for OPILL |
| What excipients (inactive ingredients) are in OPILL? | OPILL excipients list |
| DailyMed Link: | OPILL at DailyMed |
US Patents and Regulatory Information for OPILL
OPILL is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratoire Hra | OPILL | norgestrel | TABLET;ORAL | 017031-001 | Approved Prior to Jan 1, 1982 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPILL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Laboratoire Hra | OPILL | norgestrel | TABLET;ORAL | 017031-001 | Approved Prior to Jan 1, 1982 | 3,666,858 | ⤷ Start Trial |
| Laboratoire Hra | OPILL | norgestrel | TABLET;ORAL | 017031-001 | Approved Prior to Jan 1, 1982 | 3,959,322 | ⤷ Start Trial |
| Laboratoire Hra | OPILL | norgestrel | TABLET;ORAL | 017031-001 | Approved Prior to Jan 1, 1982 | 3,850,911 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPILL
See the table below for patents covering OPILL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 716736 | ⤷ Start Trial | |
| Cyprus | 658 | Pharmaceutical compositions | ⤷ Start Trial |
| Denmark | 130949 | ⤷ Start Trial | |
| United Kingdom | 1204171 | ⤷ Start Trial | |
| United Kingdom | 1204172 | ⤷ Start Trial | |
| Ireland | 32912 | PHARMACEUTICAL COMPOSITIONS | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPILL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 122015000093 | Germany | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 |
| 1453521 | CA 2016 00016 | Denmark | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
| 1453521 | 93156 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 1453521 | 300814 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | 39/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | 15C0050 | France | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
DrugChatter Q&A for OPILL
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch